Thiazolidinediones—the Ongoing Debate

References 

1. US Food and Drug Administration  . Rezulin to be withdrawn from the market. HHS News . Available at: www.fda.gov/bbs/topics/NEWS/NEW00721.html March 21, 2000; Accessed August 3, 2007
2. Nissen SE , Wolski K . Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes . N Engl J Med . 2007;356(24):2457–2471
   • CrossRef
3. Psaty BM , Furberg CD . The record on rosiglitazone and the risk of myocardial infarction . N Engl J Med . 2007;357(1):67–69
   • CrossRef
4. Richter B , Bandeira-Echtler E , Bergerhoff K , Clar C , Ebrahim Sh . Rosiglitazone for type 2 diabetes mellitus . Cochrane Database Syst Rev . 2007;3: CD006063
5. US Food and Drug Administration  . Rosiglitazone maleate (marketed as Avandia, Avandamet, and Avandaryl) information. FDA Alert . Available at: www.fda.gov/cder/drug/infopage/rosiglitazone/default.htm May 21, 2007; Accessed August 2, 2007
6. US Food and Drug Administration Endocrinology Committee transcript  . Available at: www.fda.gov/bbs/transcripts/transcript072707.pdf Accessed August 3, 2007
7. Bolen S , Feldman L , Vassy J , et al.   Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus . Ann Intern Med . 2007;47; Available at: www.annals.org/cgi/content/full/0000605-200709180-00178vl Accessed August 3, 2007
8. US Food and Drug Administration  . Manufacturers of some diabetes drugs to strengthen warning on heart failure risk. FDA News . Available at: www.fda.gov/bbs/topics/NEWS/2007/NEW01683.html August 14, 2007; Accessed August 16, 2007
9. Diamond GA , Bax L , Kaul S . Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death . Ann Intern Med . 2007;147; Available at: http://www.annals.org Accessed August 3, 2007